← Back to patent-cliff list
GW-5282
Tier C — Watch / tradeGW-5282
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：EZH1, EZH2
Indications (approved)：T-cell lymphoma, Solid tumour, Non-Hodgkin lymphoma, B-cell lymphoma, Castration-resistant prostate cancer
Regional status
US
-
EU
-
China
Phase II
2025-06-26
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of GW-5282?
Approved indications include: T-cell lymphoma, Solid tumour, Non-Hodgkin lymphoma, B-cell lymphoma, Castration-resistant prostate cancer.
When does the GW-5282 patent expire?
No public expiry year is available for GW-5282 yet; this page updates once verified.
How do I get a quote for GW-5282 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30